AUTL

Autolus Therapeutics Plc

A London-based biotech that engineers living immune cells called CAR-T cells into "living drugs" to fight blood cancers. Its lead therapy, marketed as Aucatzyl, treats adults with a hard-to-treat form of acute lymphoblastic leukemia. The company spun out of University College London in 2011, and its name comes from the Greek word "autos" ("self"), reflecting how it reprograms a patient's own cells to attack their cancer.

American Depositary Receipts (Sponsored ADR)